Comparative Pharmacology
Head-to-head clinical analysis: BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN versus IBUPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN versus IBUPROFEN SODIUM.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs IBUPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
None Documented
None Documented
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and pH-dependent: alkaline urine increases clearance.
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Category D/X
Category D/X
NSAID / Antiplatelet
NSAID